Compare · DAVI vs RMD
DAVI vs RMD
Side-by-side comparison of Davion Healthcare Plc (DAVI) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DAVI and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $33.66B, about 1027.8x DAVI ($32.8M).
- Over the past year, DAVI is down 86.8% and RMD is down 6.6% - RMD leads by 80.2 points.
- RMD has been more active in the news (6 items in the past 4 weeks vs 1 for DAVI).
- RMD has more recent analyst coverage (25 ratings vs 0 for DAVI).
- Company
- Davion Healthcare Plc
- ResMed Inc.
- Price
- -
- -
- Market cap
- $32.8M
- $33.66B
- 1M return
- -86.81%
- +2.89%
- 1Y return
- -86.81%
- -6.65%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 6
- Recent ratings
- 0
- 25
Davion Healthcare Plc
Davion Healthcare Plc is a next-generation digital healthcare company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies outside traditional clinical environments. The Company's flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion's broader portfolio includes technologies addressing circulation and foot health, testicular health, skin anomalies, wound monitoring, blood pressure and other areas of preventive healthcare. Davion's growth strategy combines the development and commercialisation of its proprietary technologies with complementary acquisitions intended to expand the Group's product portfolio and commercial, manufacturing and distribution capabilities.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest DAVI
Latest RMD
- ResMed downgraded by Canaccord Genuity
- SEC Form 10-Q filed by ResMed Inc.
- SEC Form 8-K filed by ResMed Inc.
- Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
- Global General Counsel Rider Michael J sold $102,000 worth of ResMed Common Stock (400 units at $255.00) as part of a pre-agreed trading plan (SEC Form 4)
- Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.
- Chairman and CEO Farrell Michael J. sold $1,129,637 worth of ResMed Common Stock (4,991 units at $226.33) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.